BioSpace News Archive

Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle delivery technology, today announced the addition of seasoned life sciences executive, Dieter Weinand , to its Board of Directors.

Enzychem Lifesciences (KOSDAQ: 183490), announced today that it has completed patient enrollment in Stage 2 of its Phase 2 clinical trial of EC-18 in chemoradiation induced oral mucositis (CRIOM).

Each year the National Kidney Foundation considers the work of hundreds of specialists in the field of nephrology and selects those who most exemplify the relentless efforts of NKF to enhance the lives of patients through action, education, and accelerating change.

Brings prior experience as US Representative to the World Health Organization Executive Board and expertise in health care delivery, health policy, international affairs and pandemic influenza planning to FluroTest team

Jennifer Wargo, M.D., leads research on link between microbiome and cancer treatment and recently co-authored Science review with Micronoma founders

Charles River Laboratories International, Inc. (NYSE: CRL) and Valence Discovery today announced the formation of a strategic partnership to provide clients access to Valence’s artificial intelligence platform for molecular property prediction,

Brooklyn ImmunoTherapeutics , Inc. (NYSE American: BTX) (“Brooklyn” or “the Company”), a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced the appointment of Howard J. Federoff, M.D., Ph.D., as Chief Executive Officer and President and a director as of 16 April 2021.

IM Therapeutics, Inc., a clinical-stage company developing novel, first-in-class therapies targeting human leukocyte antigens (HLAs) to treat autoimmune diseases, announced today that David Alleva, Ph.D., has joined its management team as Vice President, Immunology.

Findings from an analysis of the first 500 patients enrolled in the SPHERE registry found more than three-quarters of pulmonary arterial hypertension patients treated with UPTRAVI® either maintained or reduced their one-year mortality risk score.

Valeo Pharma Inc . , a Canadian specialty pharmaceutical company, today announced that it has completed its negotiations and entered into a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding Redesca® and Redesca HP®, its low molecular weight heparin (“LMWH”) biosimilar, for the prevention and treatment of thromboembolic disorders.